Cognition and MRI Markers in MS Patients With Aubagio® Treatment

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 21, 2019

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
OTHER

Clinical assessment

EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded

OTHER

Ecological evaluation

Virtual reality task : Urban DailyCog© and Actual reality

OTHER

Neuropsychological evaluation

cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function

OTHER

Psychological evaluation

questionnaires for depression, anxiety and fatigue

DEVICE

MRI Evaluation

morphological MRI and resting state functional MRI (fMRI)

Trial Locations (1)

Unknown

CHU de Bordeaux - Service de neurologie, Bordeaux

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University Hospital, Bordeaux

OTHER

NCT03768648 - Cognition and MRI Markers in MS Patients With Aubagio® Treatment | Biotech Hunter | Biotech Hunter